Work

Total Reversal of ALS Confirmed by EMG Normalization, Structural Reconstitution, and Neuromuscular–Molecular Restoration Achieved Through Computerized Brain-Guided Reengineering of the 1927 Nobel Prize Fever Therapy: A Case Report

Year: 2025

Type: article

Abstract: Background: Neurological disorders are the leading cause of disability, affecting over three billion people. Amyotrophic lateral sclerosis (ALS) is among the most feared and uniformly fatal neurodegenerative diseases, with no therapy capable of restoring function. Methods: We report the first application of therapeutic fever to ALS using Computerized Brain-Guided Intelligent Thermofebrile Therapy (CBIT²). This fully noninvasive treatment, delivered through FDA-approved computerized platform, digitally reengineers the 1927 Nobel Prize–recognized malarial fever therapy into a modern treatment guided by the Brain–Eyelid Thermoregulatory Tunnel. CBIT² induces therapeutic fever through synchronized hypothalamic feedback, activating heat shock proteins to restore proteostasis and neuronal function. Case presentation: A 56-year-old woman with rapidly progressive ALS was diagnosed at the Mayo Clinic, based on electromyography showing denervation and fasciculations corroborated by neurological and MRI findings; and patient was informed of an expected 3–5-year survival. Northwestern University independently confirmed the diagnosis and maintained her on FDA-approved ALS drugs (riluzole and edaravone). Her condition worsened and she underwent CBIT², resulting in: (i) electrophysiological reversal with disappearance of denervation and fasciculations; (ii) biomarker correction, including reductions in neurofilament and homocysteine, besides IL-10 normalization (previously linked to mortality) alongside robust HSP70 induction; (iii) restoration of gait, swallowing, respiration, speech, and cognition; and (iv) return to complex motor tasks, including golf and pickleball. Discussion/Conclusion: This case provides the first documented evidence that ALS can be reversed through digitally reengineered fever therapy aligned with thermoregulation. Beyond ALS, shared protein-misfolding pathology suggests CBIT² may extend to Alzheimer’s, Parkinson’s, and related disorders. By modernizing a Nobel Prize–recognized therapeutic principle with digital precision, CBIT² establishes a framework for large-scale clinical trials. Just as fever therapy a century ago restored lost brain function in dementia paralytica and earned the 1927 Nobel Prize, CBIT² now safely harnesses the therapeutic power of fever through brain-guided modulation. Amid a global brain health crisis, where neurological disorders affect more than three billion people, fever-based therapies may provide a path to preserve thought, memory, movement, and independence for over one third of humanity.

Source: Diseases

DOI: 10.3390/diseases13110371

Authors: M Marc Abreu, Mohammad Hosseini Farid, David G Silverman

Institutions: Aventura Hospital and Medical Center, Nova Southeastern University, Yale University

Language: English

Topic: Amyotrophic Lateral Sclerosis Research

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,172